Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 765179 Monotherapy and Combination Therapy in Advanced Solid Tumors and HNSCC
NCT04958239Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2021
- Primary completion
- Apr 2026
- Countries
- 15
01
Overview
Phase 1, randomised, open-label trial of BI 765179 in solid tumor and head and neck squamous cell carcinoma (HNSCC) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose at Day 21, Dose Limiting Toxicities at Day 21 and 1 more. Started Oct 2021; status: active, not recruiting.
02
Drugs
BI 765179
03
Conditions
solid tumorhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04958239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04958239.